Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society

Moran, Lisa J.; Pasquali, Renato; Teede, Helena; Hoeger, Kathleen M.; Norman, Robert J.

doi:10.1016/j.fertnstert.2008.09.018

Cited by 355 publications

(309 citation statements)

References 100 publications

Supporting

Mentioning

284

Contrasting

Unclassified

Order By: Relevance

“…Undoubtedly, weight loss per se may improve PCOS to varying extents. In fact, a number of interventional studies with lifestyle modification with or without the association of insulin sensitizers (particularly metformin) or weight lowering drugs uniformly demonstrated a significant improvement in many key features of PCOS, including androgen blood levels (47). Unfortunately, most of these studies are short, rarely exceeding 6 months (47), which represents their major limitation.…”

Section: Effect Of Weight Loss On Pcos: Lifestyle and Bariatric Surgerymentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects

Pasquali

Diamanti-Kandarakis

Gambineri

2016

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

PCOS is a clinical heterogeneous entity of female androgen excess diagnosed by exclusion of other disorders responsible for androgen excess. The concept of secondary PCOS implies that there is a primary well-defined cause leading to the PCOS phenotype with underlying androgen overproduction, regardless of the origin. In these cases, we presume the term of 'secondary PCOS' could be used. In all these conditions, the potential complete recovery of the hyperandrogenemic state as well as the remission of the PCOS phenotype should follow the removal of the cause. If accepted, these concepts could help clinicians to perform in-depth investigations of the potential factors or disorders responsible for the development of these specific forms of secondary PCOS. Additionally, this could contribute to develop further research on factors and mechanisms involved in the development of the classic and the nonclassic PCOS phenotypes. Invited author's profileRenato Pasquali is full professor of Endocrinology & Metabolism and Director of the division of Endocrinology of the S.Orsola-Malpighi Hospital, Bologna, Italy. He also heads the School of Specialization in Endocrinology and Metabolism, University Alma Mater Studiorum of Bologna, Italy. He is a member of numerous national and international scientific societies and serves on the editorial boards of international journals. His scientific interests relate to (i) the pathophysiology and treatment of the polycystic ovary syndrome; (ii) the endocrinology of obesity (sex hormones, the hypothalamic-pituitary-adrenal axis, and the endocannabinoid system).

show abstract

Section: Effect Of Weight Loss On Pcos: Lifestyle and Bariatric Surgerymentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects

Pasquali

Diamanti-Kandarakis

Gambineri

2016

European Journal of Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the use of OCP in obese women with PCOS raises a number of concerns. High dose OCP (≥35ug of ethynylestradiol/day) appear to increase IR in both PCOS and non-PCOS populations, potentially having adverse long term consequences (Morin-Papunen et al, 2000;Meyer et al, 2007). Additionally, obesity has a significant impact on the risk of venous thromboembolism risk (Ageno et al, 2008) which can be further aggravated by the use of OCP (Martinez and Avecilla, 2007).…”

Section: The Use Of Oral Contraceptive Pills (Ocp) In Obese Pcos Patimentioning

confidence: 99%

Ovarian function and obesity—Interrelationship, impact on women's reproductive lifespan and treatment options

Rachoń

Teede

2010

Molecular and Cellular Endocrinology

128

View full text Add to dashboard Cite

Insulin resistance (IR) is a consequence of obesity, and in women it is often inextricably linked with ovarian function leading to clinical reproductive manifestations such as early menarche onset, subfertility and polycystic ovary syndrome (PCOS). Likewise, the dramatic fall in oestrogen production after menopause may contribute to weight gain and changes in adipose tissue distribution.Overall, women who are obese, especially those with reproductive complications including PCOS, have been identified as specific high risk subgroups for further progression through to prediabetes, type 2 diabetes mellitus (T2DM) and potentially cardiovascular disease (CVD). This review focuses on the interrelationship between the ovarian function and obesity as well as its treatment strategies.

show abstract

“…Obesity is present in 40-60% of the women with this pathology and 50-70% of the subjects with PCOS, either obese or of normal weight, have evidence of resistance to insulin [1]. Moreover, it has been suggested that PCOS represents a female subtype of metabolic syndrome, carrying a high risk for developing type 2 diabetes mellitus and atherosclerosis with a higher probability for coronary and cerebrovascular events [2].…”

Section: Introductionmentioning

confidence: 99%

The polycystic ovary syndrome (pcos) status and cardiovascular risk in young women

Ilie¹,

Pepene²,

Marian³

et al. 2010

Open Medicine

View full text Add to dashboard Cite

AbstractThe study investigated the presence of early vascular damage and chronic inflammation, and their relationships with hormonal and metabolic parameters in 45 young women with PCOS in comparison with thirty-two healthy age-matched controls. Hormonal and metabolic profiles, high sensitivity C-reactive protein (hsCRP), tumoral necrosis factor-alpha (TNF-α), endothelin-1 (ET-1), brachial flow-mediated vasodilation (FMD) and carotid intima-media thickness (CIMT) were determined in both groups. Compared with the controls, women with PCOS had significantly lower FMD and respectively higher ET-1 levels (p=0.001). No differences were observed between the groups in terms of CIMT or inflammatory markers. In the PCOS group, ET-1 levels were significantly correlated with only testosterone concentrations (r = 0.31, p = 0.037), whereas the hsCRP levels were independently predicted only by body mass index (BMI). Within the total group, the PCOS status was the sole significant predictor of ET-1 levels and the only independent predictor of FMD. In conclusion, there is evidence of endothelial dysfunction associated with increased levels of androgen hormones in young women with PCOS. The combination of endothelial dysfunction and coexistent obesity promoting inflammation contributes to the progression of atherogenesis in PCOS. The PCOS status should be regarded as a predictor marker of cardiovascular risk, along with well-known cardiovascular risk factors.

show abstract

Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society

Cited by 355 publications

References 100 publications

MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects

MANAGEMENT OF ENDOCRINE DISEASE: Secondary polycystic ovary syndrome: theoretical and practical aspects

Ovarian function and obesity—Interrelationship, impact on women's reproductive lifespan and treatment options

The polycystic ovary syndrome (pcos) status and cardiovascular risk in young women

Contact Info

Product

Resources

About